Comparative Pharmacology
Head-to-head clinical analysis: CECLOR versus CEFTAROLINE FOSAMIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR versus CEFTAROLINE FOSAMIL.
CECLOR vs CEFTAROLINE FOSAMIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It exhibits bactericidal activity against susceptible organisms.
Ceftaroline fosamil is a prodrug that is converted to the active metabolite ceftaroline. Ceftaroline inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA and PBP2x in Streptococcus pneumoniae, thereby preventing cross-linking of peptidoglycan.
250 mg orally every 8 hours; for severe infections, 500 mg orally every 8 hours.
600 mg IV every 12 hours infused over 1 hour
None Documented
None Documented
Terminal elimination half-life: 0.6-0.9 hours in adults with normal renal function. Prolonged to 2-3 hours in end-stage renal disease. Half-life does not increase significantly with hepatic impairment.
Terminal elimination half-life is approximately 2.6 hours in patients with normal renal function. This supports twice-daily dosing in most infections.
Primarily renal: 80-90% of unchanged drug excreted by glomerular filtration and tubular secretion within 8 hours. Biliary excretion accounts for <5%; fecal elimination negligible.
Renal excretion of unchanged ceftaroline accounts for approximately 88% of the administered dose. Biliary/fecal elimination is minimal (<6%).
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic